^Monaghan G, Clarke DJ, Povey S, See CG, Boxer M, Burchell B (септембар 1994). „Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13”. Genomics. 23 (2): 496—9. PMID7835904. doi:10.1006/geno.1994.1531.CS1 одржавање: Формат датума (веза)
Hwang MS, Lee SJ, Jeong HE, Lee S, Yoo MA, Shin JG (2010). „Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population”. Drug Metabolism and Pharmacokinetics. 25 (4): 398—402. PMID20814162. doi:10.2133/dmpk.DMPK-10-SC-021.
Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolás JM, Adín J, Armijo JA (март 2010). „Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy”. Seizure. 19 (2): 93—101. PMID20064729. S2CID17525536. doi:10.1016/j.seizure.2009.12.004.CS1 одржавање: Формат датума (веза)
Chen M, LeDuc B, Kerr S, Howe D, Williams DA (март 2010). „Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol”. Drug Metabolism and Disposition. 38 (3): 368—75. PMID20008037. S2CID10438280. doi:10.1124/dmd.109.029900.CS1 одржавање: Формат датума (веза)
Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR (децембар 2009). „Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy”. Nature Genetics. 41 (12): 1345—9. PMID19898482. S2CID21293339. doi:10.1038/ng.478.CS1 одржавање: Формат датума (веза)
Yu L, Qian M, Liu Y, Yao T, Zeng S (мај 2010). „Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9”. Chirality. 22 (4): 456—61. PMID19644937. doi:10.1002/chir.20765.CS1 одржавање: Формат датума (веза)
Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI (октобар 2009). „Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid”. Therapeutic Drug Monitoring. 31 (5): 542—8. PMID19730281. S2CID6454841. doi:10.1097/FTD.0b013e3181b1dd5e.CS1 одржавање: Формат датума (веза)
Hu M, Lui SS, Mak VW, Chu TT, Lee VW, Poon EW, Tsui TK, Ko GT, Baum L, Tam LS, Li EK, Tomlinson B (октобар 2010). „Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients”. Pharmacogenetics and Genomics. 20 (10): 634—7. PMID20679960. S2CID3475599. doi:10.1097/FPC.0b013e32833de489.CS1 одржавање: Формат датума (веза)
Blanca Sánchez M, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolas JM, Adín J, Shushtarian M, Armijo JA (април 2010). „UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study”. Therapeutic Drug Monitoring. 32 (2): 177—84. PMID20216122. S2CID44807993. doi:10.1097/FTD.0b013e3181ceecc6. hdl:10261/49808.CS1 одржавање: Формат датума (веза)